2. Signalwege
  3. Metabolic Enzyme/Protease
  4. Lipoxygenase

Lipoxygenase

LOX

Lipoxygenase

Related Products

PDF 0.84 MB

Lipoxygenases (LOXs) are a family of enzymes that are responsible for the metabolism of arachidonic and docosahexaenoic acid and for the formation of several eicosanoids and docosanoids, including leukotrienes, lipoxins and neuroprotectins. Depending on cells' redox state and other milieu conditions, these enzymes are engaged in oxidative stress and cell death mechanisms or in cell protection. Lipoxygenases are lipid peroxidizing enzymes, implicated in the pathogenesis of inflammatory and hyperproliferative diseases, which represent potential targets for pharmacological intervention.

Lipoxygenases are classified on the basis of site of arachidonate oxygenation into 5-, 8-, 9-, 11-, 12- and 15-LOX. The prominent animal LOXs are 5-LOX, 8-LOX, 12-LOX and 15-LOX, while the plant LOXs are mostly 5-LOX and 15-LOX. Among these, 5-LOX is the most predominant isoform associated with the formation of 5-hydroperoxyeicosatetraenoic acid (5-HpETE) and other bioactive lipid mediators.

Lipoxygenase Isoform Specific Products:

Lipoxygenase Isoform Comparison
Art. -Nr. Produktname Wirkung Reinheit Chemical Structure
  • HY-127170R
    3-Hydroxycoumarin (Standard)
    		Inhibitor
    3-Hydroxycoumarin (Standard) is the analytical standard of 3-Hydroxycoumarin. This product is intended for research and analytical applications. 3-hydroxycoumarin is a potent and redox inhibitor of human 15-LOX-1. 3-hydroxycoumarin is recently demonstrated to protect sea urchin reproductive cells against ultraviolet B damage.
    3-Hydroxycoumarin (Standard)
  • HY-113509B
    15(R)-Lipoxin A4
    		Activator 98.3%
    15 (R)-Lipoxin A4 (15-epi-LXA4) is a specialized pro-resolving mediator and an acetylated derivative of COX2. 15 (R)-Lipoxin A4 is present in neurons. 15 (R)-Lipoxin A4 induces the SPM synthases ALOX12 and ALOX15, as well as the pro-resolving receptor ALX. 15 (R)-Lipoxin A4 inhibits protein kinases, including JNK1/2/3, Lyn, STAT-3 and STAT-6. 15 (R)-Lipoxin A4 enhances the release of pro-resolving mediators. 15 (R)-Lipoxin A4 alleviates the pro-inflammatory phenotype of tendon-derived stromal cells. 15 (R)-Lipoxin A4 promotes the resolution of neuroinflammation. 15 (R)-Lipoxin A4 is applicable to research related to achilles tendinitis, achilles tendon rupture and Alzheimer’s disease.
    15(R)-Lipoxin A4
  • HY-106823
    Tebufelone
    		Inhibitor 99.52%
    Tebufelone (NE-11740), a nonsteroidal anti-inflammatory drug (NSAID), is a selective dual COX-2/5-lipoxygenase inhibitor. Tebufelone displays potent anti-inflammatory, analgesic and anti-pyretic properties.
    Tebufelone
  • HY-130288
    (±)13-HDHA
    		98.8%
    (±)13-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Fresh water hydra is shown to metabolize DHA to 13(R)-HDHA, presumably via the 11R-lipoxygenase activity. (±)13-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid.
    (±)13-HDHA
  • HY-N9834
    Aureusidin
    		Inhibitor
    Aureusidin is an aurone with high antioxidant and lipoxygenase inhibitory activity. Aureusidin also shows anti-inflammatory effects.
    Aureusidin
  • HY-158204
    CNB-001
    		Inhibitor
    CNB-001 is a potent and orally active 5-lipoxygenase (5-LOX) inhibitor. CNB-001 can decreases 5-LOX expression and increase proteasome activity. CNB-001 can inhibit accumulation of soluble Amyloid-β and ubiquitinated aggregated proteins. CNB-001 can inhibit apoptosis, ROS production and stabilize mitochondrial membrane potential. CNB-001 can reduce insulin resistance and increase glucose uptake. CNB-001 also exhibits anti-ischemic, anti-inflammatory effects. CNB-001 can be used for the researches of inflammation, neurological and metabolic disease, such as Alzheimer's disease, stroke and diabetes.
    CNB-001
  • HY-U00156
    Lonapalene
    		Inhibitor 99.45%
    Lonapalene (RS4317) is a topically effective 5-lipoxygenase (5-LO) inhibitor.
    Lonapalene
  • HY-10437
    Setileuton
    		Inhibitor 99.9%
    Setileuton (MK-0633) is an inhibitor for 5-lipoxygenase, that inhibits the oxidation of arachidonic acid by recombinant human 5-LO, and the production of LTB4 in calcium ionophore-stimulated human whole blood, with IC50 of 3.9 and 52 nM, respectively.
    Setileuton
  • HY-W488004
    KKII5
    		Inhibitor 98.60%
    KKII5 is a potent Lipoxygenase (LOX-1) inhibitor with an IC50 of 19 μM. KKII5 inhibits lipid peroxidation.
    KKII5
  • HY-N7162
    3-O-Acetyl-11-hydroxy-beta-boswellic acid
    		Inhibitor 98.98%
    3-O-Acetyl-11-hydroxy-beta-boswellic acid is a potent 5-lipoxygenase (5-LO) inhibitor.
    3-O-Acetyl-11-hydroxy-beta-boswellic acid
  • HY-139055
    NCTT-956
    		Inhibitor
    NCTT-956 is a very effective platelet 12-lipoxygenase (12-LOX) activity-specific inhibitor.
    NCTT-956
  • HY-117085
    Lobaric acid
    		Inhibitor
    Lobaric acid is a depsipeptide metabolite isolated from Stereocaulon lichen with antioxidant, antiproliferative, antiviral and enzyme inhibitory activities. Lobaric acid scavenges superoxide free radicals (IC50=97.9 μM) and inhibits cancer cell proliferation (EC50 of 15.2-63.9 μg/mL against leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic and lung cancer cell lines). Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC50=0.87 μM for human recombinant enzyme) and 12(S)-HETE produced by 12(S)-lipoxygenase (IC50=28.5 μM). Lobaric acid (250 μM) also reduced pathological changes in tobacco leaves infected with tobacco mosaic virus (TMV).
    Lobaric acid
  • HY-116919
    MLS000536924
    		Inhibitor 98.20%
    MLS000536924 is a potent and selective inhibitor of human epithelial 15-lipoxygenase-2 with competitive activity. MLS000536924 exhibits more than 50-fold selectivity in inhibiting h15-LOX-2 and can be effectively applied to study its role in atherosclerosis, cystic fibrosis, and ferroptosis. The binding mode of MLS000536924 shows stronger restriction of protein movement than other inhibitors, further verifying its higher biological activity.
    MLS000536924
  • HY-138148
    13(S)-HPOTrE(γ)
    		99.9%
    13(S)-HpOTrE(γ) is a monohydroxy PUFA produced by the action of soybean lipoxygenase-1 (LO-1) on γ-linolenic acid. Further action of soybean LO-1 converts 13(S)-HpOTrE(γ) to all four isomers of 6,13-DiHOTrE.2 At concentrations greater than 100 μM, 13(S)-HpOTrE(γ) inhibits the activity of soybean LO-1.
    13(S)-HPOTrE(γ)
  • HY-116124
    17(S)-HpDHA
    		99.48%
    17(S)-HpDHA is the main 15-Lipoxygenase (LOX) isoenzyme: h15-LOX-1 and h15-LOX-2 and docosahexaenoic acid (DHA). product. 17(S)-HpDHA negatively regulates epoxide synthesis via allosteric regulation. 17(S)-HpDHA also inhibits platelet aggregation with an EC50 of approximately 1 μM.
    17(S)-HpDHA
  • HY-118110
    MLS000545091
    		Inhibitor 99.92%
    MLS000545091 is a potent and selective lipoxygenase-2 (LOX-2) inhibitor with an IC50 value of 2.6 μM for h15-LOX-2.
    MLS000545091
  • HY-125975
    1-Naphthyl 3,5-dinitrobenzoate
    		Inhibitor 99.49%
    1-Naphthyl 3,5-dinitrobenzoate is a potent 5-lipoxygenase inhibitor with IC50 values of 1.04 µM and 3.6 µM for 5-LOX and mPGES-1, respectively. 1-Naphthyl 3,5-dinitrobenzoate has strong inhibition activity in the human whole blood (HWB) assay with an IC50 value of 8.6 μM. 1-Naphthyl 3,5-dinitrobenzoate can be used in research of inflammation.
    1-Naphthyl 3,5-dinitrobenzoate
  • HY-19443
    UCB-35440
    		Inhibitor 99.38%
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 can be used for the research of dermatologic inflammatory conditions.
    UCB-35440
  • HY-N10898
    (-)-Dihydroguaiaretic acid
    		Inhibitor 98.79%
    (-)-Dihydroguaiaretic acid is a Lipoxygenase inhibitor that has antioxidant activity. (-)-Dihydroguaiaretic acid inhibits the oxidation of unsaturated fatty acids and removes free radicals. (-)-Dihydroguaiaretic acid also has anticancer activity with an IC50 value of 7.49 μM (A549 cells).
    (-)-Dihydroguaiaretic acid
  • HY-112532
    REV 5901
    		Inhibitor 99.9%
    REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma.
    REV 5901
Art. -Nr. Produktname / Synonyms Application Reactivity
Lipoxygenase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.